{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:45Z","timestamp":1792511385399,"version":"4.5.0"},"reference-count":199,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Lately, the global incidence of flavivirus infection has been increasing dramatically and presents formidable challenges for public health systems around the world. Most clinically significant flaviviruses are mosquito-borne, such as the four serotypes of dengue virus, Zika virus, West Nile virus, Japanese encephalitis virus and yellow fever virus. Until now, no effective antiflaviviral drugs are available to fight flaviviral infection; thus, a highly immunogenic vaccine would be the most effective weapon to control the diseases. In recent years, flavivirus vaccine research has made major breakthroughs with several vaccine candidates showing encouraging results in preclinical and clinical trials. This review summarizes the current advancement, safety, efficacy, advantages and disadvantages of vaccines against mosquito-borne flaviviruses posing significant threats to human health.<\/jats:p>","DOI":"10.3390\/v15040813","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T03:07:57Z","timestamp":1679540877000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development"],"prefix":"10.3390","volume":"15","author":[{"given":"Bingan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtian","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-1260","authenticated-orcid":false,"given":"Xijing","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/erv.11.180","article-title":"Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex","volume":"11","author":"Lobigs","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00239-020-09953-1","article-title":"Protein Evolution in the Flaviviruses","volume":"88","author":"Arenas","year":"2020","journal-title":"J. Mol. Evol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coviro.2014.09.011","article-title":"Regulation of Flavivirus RNA synthesis and replication","volume":"9","author":"Selisko","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2092","DOI":"10.1002\/rmv.2092","article-title":"Structure and function of cis-acting RNA elements of flavivirus","volume":"30","author":"Liu","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pbiomolbio.2018.09.001","article-title":"Single-molecule studies of flavivirus envelope dynamics: Experiment and computation","volume":"143","author":"Sharma","year":"2019","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/14760584.3.2.199","article-title":"Recent advancement in flavivirus vaccine development","volume":"3","author":"Chang","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses","volume":"67","author":"Brandriss","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1099\/0022-1317-69-11-2741","article-title":"Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain","volume":"69","author":"Cecilia","year":"1988","journal-title":"J. Gen. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jmv.1890290211","article-title":"Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies","volume":"29","author":"Zhang","year":"1989","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1128\/JVI.72.4.3076-3081.1998","article-title":"Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein","volume":"72","author":"Kreil","year":"1998","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Qian, X., and Qi, Z. (2022). Mosquito-Borne Flaviviruses and Current Therapeutic Advances. Viruses, 14.","DOI":"10.3390\/v14061226"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.clinthera.2017.07.001","article-title":"Progress and Works in Progress: Update on Flavivirus Vaccine Development","volume":"39","author":"Collins","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0065-3527(08)00402-8","article-title":"Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses","volume":"72","author":"Widman","year":"2008","journal-title":"Adv. Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14760584.2019.1574575","article-title":"Aiming at the heart: The capsid protein of dengue virus as a vaccine candidate","volume":"18","author":"Lazo","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1080\/21645515.2019.1643676","article-title":"Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?","volume":"15","author":"Galula","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cbdd.13357","article-title":"Selection-based design of in silico dengue epitope ensemble vaccines","volume":"93","author":"Murphy","year":"2019","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1128\/JVI.79.9.5516-5528.2005","article-title":"Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys","volume":"79","author":"Blaney","year":"2005","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2021.06.083","article-title":"Implementation strategies for the first licensed dengue vaccine: A meeting report","volume":"39","author":"Fongwen","year":"2021","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: An analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/milmed\/usaa340","article-title":"Modeling Zika Vaccination Combined With Vector Interventions in DoD Populations","volume":"186","author":"Burgess","year":"2021","journal-title":"Mil. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.vaccine.2019.05.066","article-title":"Purification of flavivirus VLPs by a two-step chomatographic process","volume":"37","author":"Lima","year":"2019","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.micinf.2018.03.001","article-title":"Rapid response to an emerging infectious disease\u2014Lessons learned from development of a synthetic DNA vaccine targeting Zika virus","volume":"20","author":"Kudchodkar","year":"2018","journal-title":"Microbes Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"a028811","DOI":"10.1101\/cshperspect.a028811","article-title":"Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination","volume":"10","author":"Whitehead","year":"2018","journal-title":"Cold Spring Harb. Perspect Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/14760584.2021.1945447","article-title":"Current development of Zika virus vaccines with special emphasis on virus-like particle technology","volume":"20","author":"Cimica","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e15272","DOI":"10.7554\/eLife.15272","article-title":"Mapping global environmental suitability for Zika virus","volume":"5","author":"Messina","year":"2016","journal-title":"eLife"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e08347","DOI":"10.7554\/eLife.08347","article-title":"The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus","volume":"4","author":"Kraemer","year":"2015","journal-title":"eLife"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1080\/21645515.2020.1730657","article-title":"Zika vaccine pre-clinical and clinical data review with perspectives on the future development","volume":"16","author":"Thomas","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bpobgyn.2021.03.009","article-title":"Future vaccines in pregnancy","volume":"76","author":"Vress","year":"2021","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.virol.2020.07.014","article-title":"Enhanced effect of modified Zika virus E antigen on the immunogenicity of DNA vaccine","volume":"549","author":"In","year":"2020","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika Virus Infection in Pregnant Women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.vaccine.2011.04.058","article-title":"Protection provided by a recombinant ALVAC(\u00ae)-WNV vaccine expressing the prM\/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain","volume":"29","author":"Minke","year":"2011","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2746\/042516407X217416","article-title":"Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model","volume":"39","author":"Long","year":"2007","journal-title":"Equine Vet. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.biotechadv.2012.03.004","article-title":"Research advances in plant-made flavivirus antigens","volume":"30","author":"Giulietti","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/fmb.14.67","article-title":"Technologies for the development of West Nile virus vaccines","volume":"9","author":"Ulbert","year":"2014","journal-title":"Future Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.vaccine.2008.03.009","article-title":"Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system","volume":"26","author":"Widman","year":"2008","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3201\/eid1108.050289b","article-title":"Virology, pathology, and clinical manifestations of West Nile virus disease","volume":"11","author":"Hayes","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jcv.2013.02.020","article-title":"West Nile virus infections in humans\u2013focus on Greece","volume":"58","author":"Papa","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_42","unstructured":"(2002). Intrauterine West Nile virus infection\u2013New York, 2002. MMWR Morb. Mortal. Wkly. Rep., 51, 1135\u20131136."},{"key":"ref_43","unstructured":"(2002). Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002. MMWR Morb. Mortal. Wkly. Rep., 51, 877\u2013878."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1542\/peds.113.5.1375","article-title":"West Nile virus infection: A pediatric perspective","volume":"113","author":"Hayes","year":"2004","journal-title":"Pediatrics"},{"key":"ref_45","unstructured":"(2002). Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb. Mortal. Wkly. Rep., 51, 973\u2013974."},{"key":"ref_46","unstructured":"(2003). Detection of West Nile virus in blood donations--United States, 2003. MMWR Morb. Mortal. Wkly. Rep., 52, 769\u2013772."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/ijerph10094200","article-title":"A review of vaccine approaches for West Nile virus","volume":"10","author":"Iyer","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/21645515.2017.1414763","article-title":"Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children","volume":"14","author":"Chanthavanich","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1016\/j.vaccine.2018.06.040","article-title":"Genetic and neuroattenuation phenotypic characteristics and their stabilities of SA14-14-2 vaccine seed virus","volume":"36","author":"Liu","year":"2018","journal-title":"Vaccine"},{"key":"ref_50","first-page":"11","article-title":"Japanese encephalitis virus: Ecology and epidemiology","volume":"267","author":"Endy","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/nm1144","article-title":"Emerging flaviviruses: The spread and resurgence of Japanese encephalitis, West Nile and dengue viruses","volume":"10","author":"Mackenzie","year":"2004","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.qco.0000178823.28585.ad","article-title":"New developments in flavivirus vaccines with special attention to yellow fever","volume":"18","author":"Pugachev","year":"2005","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/22221751.2022.2049983","article-title":"Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo","volume":"11","author":"Qian","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow Fever\u2014Once Again on the Radar Screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"de Freitas, C.S., Higa, L.M., Sacramento, C.Q., Ferreira, A.C., Reis, P.A., Delvecchio, R., Monteiro, F.L., Barbosa-Lima, G., James Westgarth, H., and Vieira, Y.R. (2019). Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007072"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1128\/JVI.02505-14","article-title":"Overlapping and distinct molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus","volume":"88","author":"Liu","year":"2014","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yang, D., Li, N.L., Wei, D., Liu, B., Guo, F., Elbahesh, H., Zhang, Y., Zhou, Z., Chen, G.Y., and Li, K. (2019). The E3 ligase TRIM56 is a host restriction factor of Zika virus and depends on its RNA-binding activity but not miRNA regulation, for antiviral function. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007537"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/157489106775244055","article-title":"Recent advances in flavivirus antiviral drug discovery and vaccine development","volume":"1","author":"Ray","year":"2006","journal-title":"Recent Pat. AntiInfect. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0020-7519(03)00063-8","article-title":"Traditional and novel approaches to flavivirus vaccines","volume":"33","author":"Pugachev","year":"2003","journal-title":"Int. J. Parasitol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1073\/pnas.0307145101","article-title":"Mimicking live flavivirus immunization with a noninfectious RNA vaccine","volume":"101","author":"Kofler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/14760584.7.5.569","article-title":"Dengue vaccines for travelers","volume":"7","author":"Deen","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1016\/j.vaccine.2004.11.069","article-title":"Recombination and flavivirus vaccines: A commentary","volume":"23","author":"Monath","year":"2005","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1016\/j.vaccine.2011.05.032","article-title":"Characterization of the RepliVax platform for replication-defective flavivirus vaccines","volume":"29","author":"Rumyantsev","year":"2011","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/j.vaccine.2008.03.010","article-title":"Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis","volume":"26","author":"Ishikawa","year":"2008","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4269\/ajtmh.2010.09-0310","article-title":"Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection","volume":"82","author":"Widman","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/vim.2004.17.461","article-title":"Flavivirus immunization with capsid-deletion mutants: Basics, benefits, and barriers","volume":"17","author":"Mandl","year":"2004","journal-title":"Viral. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Hombach","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3389\/fimmu.2020.01252","article-title":"Anti-dengue Vaccines: From Development to Clinical Trials","volume":"11","author":"Souza","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine","volume":"223","author":"Michlmayr","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2101","DOI":"10.1002\/rmv.2101","article-title":"Dengue: Status of current and under-development vaccines","volume":"30","author":"Redoni","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000394","article-title":"Dengue vaccines: Implications for dengue control","volume":"30","author":"Robinson","year":"2017","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Ooi","year":"2019","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J. Virol."},{"key":"ref_75","first-page":"129","article-title":"Dengue vaccine candidates in development","volume":"338","author":"Durbin","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1016\/j.vaccine.2011.06.101","article-title":"Genetic stability of a dengue vaccine based on chimeric yellow fever\/dengue viruses","volume":"29","author":"Mantel","year":"2011","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated Tetravalent Dengue Vaccine in Dengue-na\u00efve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination","volume":"225","author":"Biswal","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/infdis\/jiv258","article-title":"CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate","volume":"212","author":"Chu","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_80","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull. World Health Organ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"Sun","year":"2001","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1016\/j.vaccine.2011.07.054","article-title":"Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines","volume":"29","author":"Wiggan","year":"2011","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/infdis\/170.1.27","article-title":"Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine","volume":"170","author":"Dharakul","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/S0264-410X(01)00236-5","article-title":"Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine","volume":"19","author":"Rothman","year":"2001","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2004.11.040","article-title":"Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: Interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"Tricou","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: A randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"908398","DOI":"10.3389\/fimmu.2022.908398","article-title":"Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Na\u00efve and DENV-Exposed Individuals in a Brazilian Cohort","volume":"13","author":"Silveira","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial","volume":"212","author":"George","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: A randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: A randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41467-018-02975-w","article-title":"Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Garg, H., Mehmetoglu-Gurbuz, T., and Joshi, A. (2018). Recent Advances in Zika Virus Vaccines. Viruses, 10.","DOI":"10.3390\/v10110631"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1099\/vir.0.059436-0","article-title":"Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2","volume":"94","author":"Li","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2006.06.008","article-title":"Chimeric West Nile\/dengue virus vaccine candidate: Preclinical evaluation in mice, geese and monkeys for safety and immunogenicity","volume":"24","author":"Pletnev","year":"2006","journal-title":"Vaccine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1016\/j.vaccine.2009.07.016","article-title":"RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters","volume":"27","author":"Widman","year":"2009","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1749-6632.2001.tb02702.x","article-title":"Current status of flavivirus vaccines","volume":"951","author":"Barrett","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: The virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","article-title":"Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys","volume":"33","author":"Monath","year":"2005","journal-title":"Biologicals"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1128\/JVI.75.2.934-942.2001","article-title":"Molecular basis for attenuation of neurovirulence of a yellow fever Virus\/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)","volume":"75","author":"Arroyo","year":"2001","journal-title":"J. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/JVI.74.4.1742-1751.2000","article-title":"Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys","volume":"74","author":"Monath","year":"2000","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0042-6822(91)90034-9","article-title":"Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection","volume":"180","author":"Mason","year":"1991","journal-title":"Virology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.virol.2006.04.003","article-title":"Production and characterization of vaccines based on flaviviruses defective in replication","volume":"351","author":"Mason","year":"2006","journal-title":"Virology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/cmi.2015.76","article-title":"Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine","volume":"13","author":"Liang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.vaccine.2019.12.042","article-title":"Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals","volume":"38","author":"Burkhard","year":"2020","journal-title":"Vaccine"},{"key":"ref_116","first-page":"159","article-title":"Intradermal vaccination to protect against yellow fever and influenza","volume":"351","author":"Roukens","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2016.11.080","article-title":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","volume":"35","author":"Poore","year":"2017","journal-title":"Vaccine"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/0264-410X(95)00133-L","article-title":"Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis","volume":"13","author":"Heinz","year":"1995","journal-title":"Vaccine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.4049\/jimmunol.163.12.6756","article-title":"A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms","volume":"163","author":"Aberle","year":"1999","journal-title":"J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(20)30733-7","article-title":"Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: An observer-blind, randomised, phase 1 trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"eaao4163","DOI":"10.1126\/scitranslmed.aao4163","article-title":"Durability and correlates of vaccine protection against Zika virus in rhesus monkeys","volume":"9","author":"Abbink","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"46375","DOI":"10.1038\/srep46375","article-title":"Protective efficacy of Zika vaccine in AG129 mouse model","volume":"7","author":"Sumathy","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1016\/j.vaccine.2010.09.076","article-title":"Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate","volume":"28","author":"Inoue","year":"2010","journal-title":"Vaccine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12985-015-0282-8","article-title":"The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys","volume":"12","author":"Muraki","year":"2015","journal-title":"Virol. J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine"},{"key":"ref_128","first-page":"105","article-title":"Japanese encephalitis vaccines: Current vaccines and future prospects","volume":"267","author":"Monath","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Fan, Y.C., Chen, J.M., Chiu, H.C., Chen, Y.Y., Lin, J.W., Shih, C.C., Chen, C.M., Chang, C.C., Chang, G.J., and Chiou, S.S. (2012). Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001834"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/infdis\/161.5.878","article-title":"Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants","volume":"161","author":"Poland","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1999.61.288","article-title":"Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens","volume":"61","author":"Defraites","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/0140-6736(90)91036-A","article-title":"Further experience with Japanese encephalitis vaccine","volume":"335","author":"Sanchez","year":"1990","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1468-1331.1998.550479.x","article-title":"Neurological complications to vaccination against Japanese encephalitis","volume":"5","author":"Plesner","year":"1998","journal-title":"Eur. J. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2010","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0264-410X(99)00403-X","article-title":"Case-control study of allergic reactions to Japanese encephalitis vaccine","volume":"18","author":"Plesner","year":"2000","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0140-6736(91)92707-9","article-title":"Side-effects with Japanese encephalitis vaccine","volume":"337","author":"Andersen","year":"1991","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0140-6736(91)91531-X","article-title":"Adverse reactions to Japanese encephalitis vaccine","volume":"338","author":"Ruff","year":"1991","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: Alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_140","first-page":"1","article-title":"Japanese encephalitis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: A non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1749-6632.2001.tb02703.x","article-title":"Flavivirus DNA vaccines: Current status and potential","volume":"951","author":"Chang","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/viro.1999.9918","article-title":"Evaluation of tick-borne encephalitis DNA vaccines in monkeys","volume":"263","author":"Schmaljohn","year":"1999","journal-title":"Virology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2019-5\u2019-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for Toll-like receptor 3","volume":"279","author":"Ni","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jiz338","article-title":"Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice","volume":"220","author":"Jagger","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.adgen.2014.10.005","article-title":"Self-amplifying mRNA vaccines","volume":"89","author":"Brito","year":"2015","journal-title":"Adv. Genet."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"eaba5068","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"Davis","year":"2001","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1073\/pnas.1834270100","article-title":"DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus","volume":"100","author":"Hall","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","article-title":"Vaccine platform recombinant measles virus","volume":"53","year":"2017","journal-title":"Virus Genes"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/AOG.0000000000000581","article-title":"Vaccinations for pregnant women","volume":"125","author":"Swamy","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.coviro.2013.05.004","article-title":"Virus-induced humoral immunity: On how B cell responses are initiated","volume":"3","author":"Zabel","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/21645515.2016.1261770","article-title":"Vaccines licensed and in clinical trials for the prevention of dengue","volume":"13","author":"Torresi","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1128\/JVI.00919-06","article-title":"Nonsegmented negative-strand viruses as vaccine vectors","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J. Virol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41467-018-05276-4","article-title":"A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Cox, F., van der Fits, L., Abbink, P., Larocca, R.A., van Huizen, E., Saeland, E., Verhagen, J., Peterson, R., Tolboom, J., and Kaufmann, B. (2018). Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202820"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"Abbink","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/426824","article-title":"Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis","volume":"191","author":"Combredet","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e01485-18","DOI":"10.1128\/JVI.01485-18","article-title":"A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model","volume":"93","author":"Bodmer","year":"2019","journal-title":"J. Virol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1038\/s41598-017-15039-8","article-title":"A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model","volume":"7","author":"Brault","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e00576-17","DOI":"10.1128\/mSphere.00576-17","article-title":"Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice","volume":"3","author":"To","year":"2018","journal-title":"mSphere"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41426-017-0007-8","article-title":"Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses","volume":"7","author":"Tai","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40478-018-0572-7","article-title":"E90 subunit vaccine protects mice from Zika virus infection and microcephaly","volume":"6","author":"Zhu","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/acsinfecdis.9b00047","article-title":"Systematic Analysis of Structure Similarity between Zika Virus and Other Flaviviruses","volume":"5","author":"Hu","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Boigard, H., Alimova, A., Martin, G.R., Katz, A., Gottlieb, P., and Galarza, J.M. (2017). Zika virus-like particle (VLP) based vaccine. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005608"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Salvo, M.A., Kingstad-Bakke, B., Salas-Quinchucua, C., Camacho, E., and Osorio, J.E. (2018). Zika virus like particles elicit protective antibodies in mice. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006210"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e01415-20","DOI":"10.1128\/JVI.01415-20","article-title":"Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge","volume":"95","author":"Tandavanitj","year":"2020","journal-title":"J. Virol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization","volume":"536","author":"Dejnirattisai","year":"2016","journal-title":"Nature"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ni.3849","article-title":"Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection","volume":"18","author":"Fernandez","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"ftz026","DOI":"10.1093\/femspd\/ftz026","article-title":"Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: Design, production and immunological evaluation","volume":"77","author":"Shanmugam","year":"2019","journal-title":"Pathog. Dis."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Cabral-Miranda, G., Lim, S.M., Mohsen, M.O., Pobelov, I.V., Roesti, E.S., Heath, M.D., Skinner, M.A., Kramer, M.F., Martina, B.E.E., and Bachmann, M.F. (2019). Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines, 7.","DOI":"10.3390\/vaccines7030072"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"13679","DOI":"10.1038\/ncomms13679","article-title":"Neutralization mechanism of a highly potent antibody against Zika virus","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1016\/j.vaccine.2005.02.020","article-title":"Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge","volume":"23","author":"Karaca","year":"2005","journal-title":"Vaccine"},{"key":"ref_188","first-page":"65","article-title":"Safe and effective poxvirus vectors--NYVAC and ALVAC","volume":"82","author":"Paoletti","year":"1994","journal-title":"Dev. Biol. Stand."},{"key":"ref_189","first-page":"221","article-title":"Recombinant canarypoxvirus vaccine carrying the prM\/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge","volume":"18","author":"Minke","year":"2004","journal-title":"Arch. Virol. Suppl."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jis328","article-title":"Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection","volume":"206","author":"Brandler","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11262-008-0321-2","article-title":"Complete genome analysis and virulence characteristics of the Louisiana West Nile virus strain LSU-AR01","volume":"38","author":"Iyer","year":"2009","journal-title":"Virus Genes"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model","volume":"9","author":"Julander","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever--challenges for the development and use of vaccines","volume":"357","author":"Monath","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","article-title":"Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe","volume":"26","author":"Douam","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2010.10-0001","article-title":"Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States","volume":"82","author":"Monath","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41426-018-0128-8","article-title":"Yellow fever in the diagnostics laboratory","volume":"7","author":"Domingo","year":"2018","journal-title":"Emerg Microbes Infect."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcv.2012.08.024","article-title":"Flaviviruses and their antigenic structure","volume":"55","author":"Heinz","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.coviro.2012.12.001","article-title":"Flaviviruses: Braking the entering","volume":"3","author":"Pierson","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1128\/JVI.75.17.8259-8267.2001","article-title":"Tick-borne Langat\/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: Evaluation in rhesus monkeys and in mosquitoes","volume":"75","author":"Pletnev","year":"2001","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:09Z","timestamp":1760122869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":199,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["v15040813"],"URL":"https:\/\/doi.org\/10.3390\/v15040813","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}